Global Harmonization Of Combination Product Regulation: EU vs US
This article was originally published in Clinica
Executive Summary
Wherever you are in the world, the regulation of many different drug/device combination products is highly complex and costly. Yet the number of products being developed in combination is soaring. In this article, Neil O'Flaherty and Roberto Cursano, partners at law firm Baker & McKenzie, review the likelihood of global regulatory harmonization in this area, focusing on the differences between the EU and the US
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.